Regulatory nod gives push to a potentially powerful combination in acute myeloid leukaemia
Regulatory nod gives push to a potentially powerful combination in acute myeloid leukaemia
A new antibody-drug conjugate brings hope for patients with lung cancer who have few options
Mid-stage results show meaningful reductions in pathological protein, setting stage for later-phase trials
Combination therapy delivers promising efficacy and manageable safety in PD-1 refractory head and neck squamous cell carcinoma
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
Big capital flows into companies marrying AI with cancer treatments suggest early-stage clinical research is shifting its centre …
Oral brain-penetrant NLRP3 inhibitor and new collaborations place BioAge at center of metabolic aging drug development
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
TRANQUILITY trial results strengthen case for pacibekitug as a potential quarterly IL-6 inhibitor for cardiovascular inflammation in chronic …
FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
